Status:
COMPLETED
Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence
Lead Sponsor:
Vanderbilt University
Conditions:
End Stage Renal Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Hyperphosphatemia in end-stage renal disease (ESRD) patients is a non-traditional risk factor for all-cause and cardiovascular mortality. Non-adherence to phosphate binders is as high as 74% in ESRD p...
Eligibility Criteria
Inclusion
- Adults age 18 years or older
- Receiving phosphate binder therapy currently
- English speaking
Exclusion
- Non- English speaking
- Known diagnosis of psychosis or dementia, limiting ability to provide informed consent
- Any medical condition that precludes participation in the study including deafness, dying etc.
- Initial Morisky Medication Adherence score greater than 6
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT02215655
Start Date
September 1 2014
End Date
May 1 2015
Last Update
April 29 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232